GcMAF-Forte is administered by subcutaneous (SC) or intravenous (IV) injection, 1 time per week (or as prescribed by the treating medical doctor) using a Size 26G x 1/2″ (0.45 x 13 mm) or Size 27G needle with a 2.5 ml or 2 ml syringe (single use, sterile disposable). The larger 2.5 ml syringe is easier to use due to the shorter plunger stroke distance necessary during injection. Diabetes needles may also be sufficient for administration of GcMAF-Forte, although these are a finer needle.
Treatment in our clinics has also been by subcutaneous (SC) and intravenous (IV) injection, although IM and SC injection is by far the most common means of administration for most patients.
Various other methods of administration are possible:
Intravenous (IV) injection
GcMAF-Forte may be administered by intravenous (IV) infusion (drip) or by push IV. The usual dose is 2 ml once a week in 20 ml or more saline. When given by push IV, 20 ml saline and GcMAF-Forte solution is administered in a 20 or 30 ml syringe for 3 minutes or longer.
Inhalation of GcMAF-Forte using a Nebulizer
Another option of administration is using a Nebulizer to activate macrophages in the bronchus-associated lymphoid tissue (BALT) of the lungs, for example, using a device such as the Omron NE-U22 Portable Nebuliser. This method of administration is particularly well suited to diseases of the lungs where local administration can have greater effect.
Omron NE-U22 Portable Nebuliser for administration in the lungs to activate macrophages in the Bronchus-Associated Lymphoid Tissue (BALT) of the lungs.